What is Arine?
Arine operates at the intersection of artificial intelligence and healthcare, focusing on optimizing medication management. The platform integrates sophisticated analytics with deep clinical knowledge to deliver personalized recommendations. This enables health plans and provider organizations to improve medication safety, adherence, and overall effectiveness for their members. By addressing critical aspects of pharmaceutical care, Arine aims to reduce healthcare expenditures while simultaneously elevating the quality of patient treatment.
How much funding has Arine raised?
Arine has raised a total of $70M across 3 funding rounds:
Series A
$11M
Series B
$29M
Series C
$30M
Series A (2021): $11M with participation from 111° West Capital Partners, Scan Group, Katalyst Ventures, and Magellan Health
Series B (2022): $29M led by Super Capital Group, New Leaf Venture Partners, MBX Capital, Katalyst Ventures, and 111° West Capital
Series C (2025): $30M supported by Kaiser Permanente and Town Hall Ventures
Key Investors in Arine
Kaiser Permanente
Kaiser Permanente is a leading not-for-profit integrated healthcare organization known for its comprehensive medical services and health plans. Founded in 1945, it operates a vast network of hospitals and clinics across the United States, focusing on preventive care and improving member health outcomes through an innovative, patient-centered model.
Town Hall Ventures
Town Hall Ventures is a venture capital firm established in 2018 that invests in founders tackling significant healthcare challenges, particularly for underserved communities. They focus on innovative solutions in areas like school-based mental health and rural healthcare, providing substantial resources to scale transformative healthcare businesses.
Katalyst Ventures
Katalyst Ventures is an early-stage venture fund specializing in promising technology companies, particularly those leveraging artificial intelligence for enterprise applications in traditional industries. They invest in visionary entrepreneurs with strong character and the potential to build impactful, global companies.
What's next for Arine?
With its recent major strategic investment, Arine is poised for significant expansion and further development of its AI-driven solutions. The company's focus on improving medication optimization suggests a trajectory towards deeper integration within healthcare systems, potentially expanding its services to a broader range of patient populations and complex conditions. Future growth may involve enhancing its predictive analytics capabilities and forging new partnerships with healthcare providers and payers to further its mission of cost reduction and improved patient care. This strategic financing will likely fuel innovation in personalized medicine and health plan management.
See full Arine company page
